A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer

This study is testing a new investigational drug in men with prostate cancer that has spread and is no longer responding to hormone therapy (castration-resistant prostate cancer). The cancer must be detectable by a specialized scan called a PSMA PET/CT scan. **You may be eligible if...** - You are 18 or older and have confirmed prostate cancer - Your cancer has spread and is castration-resistant (testosterone is at very low levels but cancer continues to grow) - Your cancer shows up on a PSMA PET/CT scan - You have already received at least one hormone-based treatment (like enzalutamide or abiraterone) - You have also received at least one prior taxane chemotherapy (like docetaxel), or are not a good candidate for chemotherapy - You are in reasonably good health (ECOG 0-1) and have a life expectancy of more than 6 months **You may NOT be eligible if...** - Your testosterone is not adequately suppressed - You have not had appropriate prior treatments - Your organ function is not adequate for this experimental therapy Talk to your doctor to see if this trial is right for you.